Showing results (171-180 of 193) with videos related to

Sort By:
Pageof 20
BMJ (Clinical Research Ed.)|September 10, 2020
Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality ScoreStephen R Knight, Antonia Ho, Riinu Pius, et al.
Thorax|November 23, 2021
Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation ProtocolStephen R Knight, Rishi K Gupta, Antonia Ho, et al.
The Journal of Infection|December 3, 2025
Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trialE Kelly, M Greenland, P de Whalley, et al.
Lancet (London, England)|August 9, 2021
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trialXinxue Liu, Robert H Shaw, Arabella S V Stuart, et al.
Plos One|January 5, 2012
Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspectiveCharles R Beck, Bruce C McKenzie, Ahmed B Hashim, et al.
The Lancet. Infectious Diseases|September 12, 2024
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trialVictoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, et al.
Influenza and Other Respiratory Viruses|September 17, 2013
Influenza vaccination for immunocompromised patients: summary of a systematic review and meta-analysisCharles R Beck, Bruce C McKenzie, Ahmed B Hashim, et al.
The Lancet. Respiratory Medicine|June 11, 2022
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trialRobert H Shaw, Xinxue Liu, Arabella S V Stuart, et al.
The Journal of Infection|April 7, 2023
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccinesRobert H Shaw, Melanie Greenland, Arabella S V Stuart, et al.
The Lancet. Respiratory Medicine|January 14, 2021
Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort studyRishi K Gupta, Ewen M Harrison, Antonia Ho, et al.
Pageof 20